The evidence showed a potential ferroptosis-inducing therapy strategy that ipatasertib could inhibit HSPB1 phosphorylation, enhancing erastin-induced ferroptosis, and thus killing tumor cells. This evidence concerns the gene HSPB1 and neoplasm.